DD266118A5 - Verfahren zur herstellung von neuen igg-antikoerpern der maus mit anti-humaninterferon-alpha 2-, -omega 1- und antihybridinterferonspezifitaet - Google Patents

Verfahren zur herstellung von neuen igg-antikoerpern der maus mit anti-humaninterferon-alpha 2-, -omega 1- und antihybridinterferonspezifitaet Download PDF

Info

Publication number
DD266118A5
DD266118A5 DD87300598A DD30059887A DD266118A5 DD 266118 A5 DD266118 A5 DD 266118A5 DD 87300598 A DD87300598 A DD 87300598A DD 30059887 A DD30059887 A DD 30059887A DD 266118 A5 DD266118 A5 DD 266118A5
Authority
DD
German Democratic Republic
Prior art keywords
leu
ser
arg
gin
interferon
Prior art date
Application number
DD87300598A
Other languages
German (de)
English (en)
Inventor
Rudolf Hauptmann
Peter Swetly
Peter Meindl
Guenther Adolf
Edgar Falkner
Gerhard Bodo
Ingrid Maurer-Fogy
Original Assignee
��������@���������������@����������������������@���k��
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ��������@���������������@����������������������@���k�� filed Critical ��������@���������������@����������������������@���k��
Publication of DD266118A5 publication Critical patent/DD266118A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Soft Magnetic Materials (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DD87300598A 1986-03-10 1987-03-09 Verfahren zur herstellung von neuen igg-antikoerpern der maus mit anti-humaninterferon-alpha 2-, -omega 1- und antihybridinterferonspezifitaet DD266118A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863607835 DE3607835A1 (de) 1986-03-10 1986-03-10 Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
DD266118A5 true DD266118A5 (de) 1989-03-22

Family

ID=6295926

Family Applications (2)

Application Number Title Priority Date Filing Date
DD87300598A DD266118A5 (de) 1986-03-10 1987-03-09 Verfahren zur herstellung von neuen igg-antikoerpern der maus mit anti-humaninterferon-alpha 2-, -omega 1- und antihybridinterferonspezifitaet
DD32350187A DD276493A5 (de) 1986-03-10 1987-03-09 Verfahren zur Herstellung eines Hybridinterferons

Family Applications After (1)

Application Number Title Priority Date Filing Date
DD32350187A DD276493A5 (de) 1986-03-10 1987-03-09 Verfahren zur Herstellung eines Hybridinterferons

Country Status (21)

Country Link
US (1) US4917887A (ko)
EP (1) EP0236920B1 (ko)
JP (1) JPS62282595A (ko)
KR (1) KR950008191B1 (ko)
AT (1) ATE81671T1 (ko)
AU (1) AU600702B2 (ko)
DD (2) DD266118A5 (ko)
DE (2) DE3607835A1 (ko)
DK (1) DK120387A (ko)
ES (1) ES2052502T3 (ko)
FI (2) FI871012A (ko)
GR (1) GR3006844T3 (ko)
HU (1) HU206896B (ko)
IE (2) IE60573B1 (ko)
IL (1) IL81832A0 (ko)
NO (1) NO870967L (ko)
NZ (1) NZ219549A (ko)
PH (1) PH27060A (ko)
PT (1) PT84427B (ko)
SU (1) SU1604164A3 (ko)
ZA (1) ZA871679B (ko)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633323A1 (de) * 1986-10-01 1988-04-07 Boehringer Ingelheim Int Neue monoklonale antikoerper gegen ifn-omega, verfahren zu ihrer herstellung und deren verwendung zur reinigung sowie zum nachweis von ifn-omega
DE3642096A1 (de) * 1986-12-10 1988-06-16 Boehringer Ingelheim Int Pferde-(gamma)-interferon
AT389318B (de) * 1987-10-22 1989-11-27 Boehringer Ingelheim Int Neue hybridomzellinien, welche neue monoklonale antikoerper gegen ifn-omega produzieren, verfahren zu ihrer herstellung und die verwendung der neuen monoklonalen antikoerper zur reinigung sowie zum nachweis von ifn-omega
US5015485A (en) * 1989-05-30 1991-05-14 Nabisco Brands, Inc. Dog biscuits having a coating containing an inorganic pyrophosphate
US5000940A (en) * 1989-05-30 1991-03-19 Nabisco Brands, Inc. Devices, compositions and the like having or containing an inorganic pyrophosphate
US5000943A (en) * 1989-05-30 1991-03-19 Nabisco Brands, Inc. Canine biscuits containing an inorganic pyrophosphate
US5000973A (en) * 1989-05-30 1991-03-19 Nabisco Brands, Inc. Nutritionally-balanced canine biscuits containing an inorganic pyrophosphate
US5047231A (en) * 1989-05-30 1991-09-10 Nabisco Brands, Inc. Raw hide containing an inorganic pyrophosphate
EP0626448A3 (de) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
ATE243045T1 (de) 1997-11-20 2003-07-15 Vical Inc Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür
US6353091B1 (en) * 1998-03-13 2002-03-05 Brown University Research Founddation Human N-type calcium channel isoform
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
CA2427194A1 (en) * 2000-11-03 2002-05-10 Biomedicines, Inc. Method for short-term and long-term drug dosimetry
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
EP1425409A4 (en) * 2001-08-12 2005-11-09 Pepgen Corp INTERFERON HYBRID / INTERFERON TAU PROTEINS, COMPOSITIONS AND METHODS OF USE THEREOF
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US20030143197A1 (en) * 2001-11-09 2003-07-31 Moran S. Mark Method for treating diseases with omega interferon
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2363112B8 (en) 2006-08-09 2018-11-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
AU2010298733B2 (en) 2009-09-28 2014-10-09 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
AU2014235003A1 (en) * 2013-03-15 2015-09-17 Janssen Biotech, Inc. Interferon alpha and omega antibody antagonists
TWI713453B (zh) * 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
IL307966A (en) 2017-01-03 2023-12-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77877C (fi) * 1979-04-20 1989-05-10 Technobiotic Ltd Foerfarande foer framstaellning och rening av human le-formig interferonprotein.
ES8302778A1 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
JPH064673B2 (ja) * 1980-11-10 1994-01-19 ゲネンテツク・インコ−ポレ−テツド ハイブリド型ヒト白血球インタフエロン
AU1155083A (en) * 1982-01-19 1983-07-28 Cetus Corporation Multiclass hybrid interferons
EP0098876A1 (en) * 1982-01-19 1984-01-25 Cetus Corporation Multiclass hybrid interferons
DE3247922A1 (de) * 1982-12-24 1984-06-28 Boehringer Ingelheim International GmbH, 6507 Ingelheim Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
DE3409966A1 (de) * 1984-03-19 1985-09-26 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von human-gammainterferon und mittel zur durchfuehrung dieses verfahrens
DE3428370A1 (de) * 1984-08-01 1986-02-13 Boehringer Ingelheim International GmbH, 6507 Ingelheim Interferon, genetische sequenzen, die hierfuer codieren, und diese produzierende organismen
ATE67786T1 (de) * 1984-08-01 1991-10-15 Boehringer Ingelheim Int Neue genetische sequenzen, die durch sie codierten interferon-peptide vom typ i und diese sie produzierende organismen.
EP0174143B1 (en) * 1984-08-27 1989-11-08 Genentech, Inc. Novel, distinct family of human leukocyte interferons, compositions containing them, methods for their production, and dna and transfected hosts therefor
EP0173935A1 (en) * 1984-08-31 1986-03-12 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
EP0205404B1 (en) * 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators

Also Published As

Publication number Publication date
US4917887A (en) 1990-04-17
SU1604164A3 (ru) 1990-10-30
FI925631A0 (fi) 1992-12-11
IE870591L (en) 1987-09-10
NO870967D0 (no) 1987-03-09
EP0236920A3 (en) 1988-03-02
EP0236920B1 (de) 1992-10-21
IE60573B1 (en) 1994-07-27
GR3006844T3 (ko) 1993-06-30
DD276493A5 (de) 1990-02-28
PT84427A (de) 1987-04-01
KR950008191B1 (ko) 1995-07-26
ES2052502T3 (es) 1994-07-16
AU6978687A (en) 1987-09-17
FI871012A (fi) 1987-09-11
NO870967L (no) 1987-09-11
PT84427B (pt) 1989-10-04
DE3782259D1 (de) 1992-11-26
FI925631A (fi) 1992-12-11
PH27060A (en) 1993-02-01
DE3607835A1 (de) 1987-09-24
KR870009020A (ko) 1987-10-22
DK120387D0 (da) 1987-03-09
EP0236920A2 (de) 1987-09-16
HUT44074A (en) 1988-01-28
ZA871679B (en) 1988-11-30
ATE81671T1 (de) 1992-11-15
JPS62282595A (ja) 1987-12-08
FI871012A0 (fi) 1987-03-09
IE940131L (en) 1987-09-10
IL81832A0 (en) 1987-10-20
HU206896B (en) 1993-01-28
AU600702B2 (en) 1990-08-23
NZ219549A (en) 1990-07-26
DK120387A (da) 1987-09-11

Similar Documents

Publication Publication Date Title
DD266118A5 (de) Verfahren zur herstellung von neuen igg-antikoerpern der maus mit anti-humaninterferon-alpha 2-, -omega 1- und antihybridinterferonspezifitaet
DE69330087T2 (de) System zur lokalisierung und kommunikation mit mobilen fahrzeugen
DE3685996T2 (de) Hybrid-interferone.
DE69519454T2 (de) Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
DE69520088T2 (de) Interferon-gamma-induzierendes Polypeptid monoklonal Antikörper, und Zusammensetzung für Interferon-gamma gebunden Krankheiten
DE69131449T2 (de) Verbesserte exotoxine aus pseudomonas mit geringer toxität bei tieren und hoher zelltötender aktivität
DE3177288T3 (de) Reife menschliche Leukozyten-Interferone, Verfahren zu ihrer bacteriellen Herstellung, Zwischenprodukte hierfür und Zusammensetzungen diese enthaltend.
DE69007975T2 (de) Fusionsprotein bestehend aus gm-csf und il-3.
DE69027961T2 (de) Protein, DNA und ihre Verwendung
DE69028671T2 (de) Löslisches extrazellulares Fragment des menschlischen IFN-beta 2/IL-6-Rezeptors, seine Herstellung und diesen Fragment enthaltende pharmazeutische Mischung
DE3587939T2 (de) Tumornekrosefaktor, Verfahren zu seiner Herstellung, denselben enthaltende Zusammensetzungen, dafür kodierende DNS und diese DNS verwendendes Testverfahren.
EP0538300B1 (de) O-glycosyliertes ifn-alpha
DE68910354T2 (de) Menschliches mutantes Angiogenin (Angiogenese-Faktor mit überlegener Angiogenin-Aktivität), Gene dafür und Methode zur Expression.
EP0271824B1 (de) Pferde-Gamma-Interferon
DE3750432T2 (de) IL-1 alpha Derivate und Medikamente.
DE3853876T2 (de) Bordetella pertussis-Toxin mit veränderter Toxizität.
CH663619A5 (de) Polypeptide, welche die aminosaeuresequenz und die biologische aktivitaet von reifem human-immuninterferon aufweisen.
DE3750915T2 (de) Für Antitumor-Polypeptide kodierende DNS, die Polypeptide und diese Polypeptide enthaltenden Antitumor-Wirkstoffe.
DE19535853C2 (de) Varianten des rekombinanten humanen Interferon-gamma, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0170204B1 (de) Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen
DE68920931T2 (de) Rekombinanter natürlicher Killerzellen-Aktivator.
DE69522492T2 (de) Verfahren zur Herstellung von Alpha-Interferon
DE69033756T2 (de) Gene, die für MACIF Proteine kodieren, Expressionsvektoren mit diesem Genen, und Transformantenzellen mit diesem Proteinen
DE69022901T2 (de) Streptokinase-Proteine, entsprechende Gene, entsprechende Plasmide und Verfahren zu deren Herstellung.
DE69331977T2 (de) Löslicher LDL-Rezeptor, seine Herstellung und Verwendung

Legal Events

Date Code Title Description
ENJ Ceased due to non-payment of renewal fee